

Ajanta House,T+91 22 6606 1000Charkop, Kandivli (West),F+91 22 6606 1200Mumbai 400 067Einfo@ajantapharma.comIndiaWwww.ajantapharma.com

21st October 2021

Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ
Mumbai – 400001	Bandra (East), Mumbai – 400 051
Dalal Street,	C/1, G Block, Bandra Kurla Complex,
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Floor, Plot no.
BSE LIMITED	National Stock Exchange of India,

Ref.: Intimation under Regulations 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations)

Dear Sirs/Madam,

Pursuant to Regulation 29 of the Listing Regulations, we hereby inform that a Meeting of the Board of Directors of the Company will be held on Friday, 29th October 2021 to *interalia*:

- Approve and take on record unaudited consolidated & standalone Financial Results of the Company for the second quarter and half year ended 30th September 2021 and
- 2. Consider declaration of interim dividend, if any, for the financial year ending 31st March 2022.
- 3. Fixation of Wednesday, 10th November 2021 as the Record Date for the payment of interim dividend, if declared.

You are requested to please take a note of the same and disseminate to all concerned.

Thanking you,

Yours faithfully,

Gaurang Shah VP – Legal & Company Secretary